Great Diamond Partners LLC Invests $618,000 in Danaher Corporation $DHR

Great Diamond Partners LLC bought a new stake in shares of Danaher Corporation (NYSE:DHR) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,126 shares of the conglomerate’s stock, valued at approximately $618,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Baird Financial Group Inc. boosted its position in Danaher by 28.1% during the 2nd quarter. Baird Financial Group Inc. now owns 1,847,491 shares of the conglomerate’s stock valued at $364,953,000 after acquiring an additional 405,785 shares in the last quarter. First Trust Advisors LP raised its position in shares of Danaher by 34.5% in the 2nd quarter. First Trust Advisors LP now owns 55,418 shares of the conglomerate’s stock worth $10,947,000 after acquiring an additional 14,217 shares in the last quarter. Guggenheim Capital LLC lifted its stake in shares of Danaher by 25.3% in the 2nd quarter. Guggenheim Capital LLC now owns 34,066 shares of the conglomerate’s stock valued at $6,729,000 after purchasing an additional 6,889 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Danaher by 53.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,973 shares of the conglomerate’s stock valued at $785,000 after purchasing an additional 1,380 shares during the period. Finally, Alpha Family Trust boosted its position in shares of Danaher by 150.0% during the second quarter. Alpha Family Trust now owns 3,000 shares of the conglomerate’s stock valued at $593,000 after purchasing an additional 1,800 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares in the company, valued at approximately $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 30,248 shares of company stock worth $6,609,663. Insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft increased their price objective on Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Robert W. Baird set a $247.00 price target on shares of Danaher in a research note on Wednesday, October 22nd. JPMorgan Chase & Co. boosted their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Finally, TD Cowen upped their price objective on shares of Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Twenty analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $245.75.

Danaher Trading Down 0.6%

Danaher stock opened at $227.13 on Friday. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The business’s fifty day moving average is $215.40 and its 200 day moving average is $204.10. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The stock has a market capitalization of $160.43 billion, a PE ratio of 46.83, a price-to-earnings-growth ratio of 4.43 and a beta of 0.89.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. During the same quarter in the prior year, the business earned $1.71 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. On average, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s payout ratio is 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.